Prevail Therapeutics

Home » Prevail Therapeutics

IPO

Prevail Therapeutics

Biotechnology

We are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases.

Symbol

PRVL

Price Range
$16.00 - $18.00

Final Shares
7,353,000

Anticipated Date
June 20, 2019

Underwriters
MORGAN STANLEY & CO. LLC,MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED,COWEN AND COMPANY, LLC

This offering is no longer available

To view the prospectus for Prevail Therapeutics IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253